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Abstract
In order to improve the presentation and immunogenicity of single epitopes, virus-like particles
(VLPs) are being used as platforms for the display of foreing epitopes on their surface. The rotavirus
major capsid protein VP6 has the ability to self-assemble into empty non-infectious VLPs. In the
present study, we analyzed the use of double layered VLPs (made up of VP2 and VP6 rotavirus
proteins) as carriers to display a 14 amino acid epitope fused to three different aminoacidic regions
of VP6 exposed on the surface of VLPs. Although all chimeric protein were correctly expressed in
insect cells, only one of them resulted in spontaneous assembly of VLPs displaying the heterologous
epitope on their surface, confirmed by sandwich ELISA and electron microscopy. Furthermore, the
injection of chimeric VLPs into mice elicited higher antibody titers than the monomeric chimeric
protein. Our results identify an specific amino acid region of VP6 which allows the insertion of at
least a 14 amino acid heterolgous epitope and demonstrate its potential as immunogenic carrier.
Background
Virus-like particles (VLPs) are complexes composed of
viral structural proteins that retain the ability to self-
assemble without requiring the presence of the viral
genome, mimicking the overall structure of virus particles.
They are considered as safe and non-infectious tools for
several purposes such as diagnostic assays [1-4], cell inter-
action studies [5,6] and vaccines [7-14]. VLPs are com-
monly more immunogenic than subunit or recombinant
immunogens based on single, monomeric proteins, and
are able to stimulate both the humoral and cellular path-
ways of the immune system. VLPs offer a promising
approach to the production of vaccines against many dis-
eases, because their repetitive, high density display of
epitopes is often effective in eliciting strong immune
responses [15]. This is further enhanced by the particulate
nature of VLPs, especially in the size range of around 40
nm that appears to be optimal for uptake of nanoparticles
by dendritic cells [16].
VLPs provide the spatial structure for the display of con-
formational epitopes and can be exploited as platforms
for the presentation of foreign epitopes or targeting mole-
cules on chimeric VLPs. This can be achieved via transcrip-
tional fusion of heterologous sequences and viral proteins
in such a way that the chimeric protein is assembled into
VLP during de novo synthesis.
Rotaviruses, members of the Reoviridae  family of seg-
mented, dsRNA genome, are the most important cause of
viral gastroenteritis in infants and young animals around
the world [17-19]. Members of this family are nonenvel-
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oped, with complex capsids containing several concentric
protein layers displaying icosahedral symmetry. Rotavi-
ruses have a triple concentric capsid. The innermost layer,
which is composed of VP2 protein, encloses the different
genomic segments of dsRNA together with VP1 and VP3
proteins. The middle layer is composed of 780 molecules
of VP6 protein, which are distributed as 260 trimers. The
outermost layer is composed of glycoprotein VP7 and
spikes of dimers of VP4 [17]. Both outer proteins are the
targets for neutralizing antibodies and define the virus G
and P serotypes, respectively. VP6 is the most abundant
protein in the virus particle, comprising about of 51% of
the total protein mass [17].
Co-expression of VP2 and VP6 in both mammalian and
insect cells results in the production of VLPs that can be
easily purified [20,21], whereas the expression of VP2
alone results in the production of pseudo-core particles or
CLPs [22,23]. Although the formation of VLPs requires
the presence of VP2, VP6 alone can form spherical or
tubular aggergates [24] and could be overexpressed and
purified in large quantities. VP6 self-assembles into differ-
ent types of particles depending on conditions such as pH,
ionic strength and divalent cation concentration.
Although VP6 is part of the middle layer of the rotavirus
mature particles, it elicits a strong humoral immune
responses after rotavirus infection. At least one strong Th
cell epitope has been mapped, which is highly conserved
in most group A rotavirus strains studied so far and it was
proposed that Th cells specific for VP6 epitopes may con-
stitute an important proportion of the total polyclonal Th
cell response against a porcine rotavirus in spleen cells
[25].
Based on the study of VP6 priming immune responses to
the external rotavirus proteins, Esquivel et al suggested
that the VP6-specific Th cells can provide cognate help to
B cells specific for neutralizing epitopes on the VP7 and/
or VP4 molecules, and that this help could be heterotypic
[26]. On the other hand, synthetic peptides spanning dif-
ferent regions of VP6 protein were able to elicit high titers
of antibodies [27,28].
Together, the ability of VP6 to form multimeric structures
and the strong immune responses that VP6 can elicit in
different species point at VP6 in an excellent candidate as
a carrier for foreign epitopes. In this report, we used the
baculovirus expression system to produce recombinant
VLPs based on rotavirus capsid VP6 and VP2 proteins
from SA11 strain of simian rotavirus. We first searched for
positions in the surface loops of VP6 that could accom-
modate a foreign 14 amino-acid peptide derived from the
simian paramyxovirus 5 (V5 epitope, [29]) without affect-
ing capsid formation and then we examined whether the
heterologous sequences inserted into these sites were dis-
played on the surfaces of the recombinant VLPs.
Results
Election of possible insertion sites into VP6 sequence
SA11 VP6 protein is 97% identity to RF VP6, In turn, RF
VP6 structural conformation is well known (PDB code:
1qhd). In order to select possible insertion sites into VP6
sequence, we analyzed the spatial conformation of 1qhd
and three regions located in loops exposed onto VLPs sur-
face were selected: the amino acids 171-172 into loop
A'A" and amino acids 311-312 and 301 to 308 both in
loop HI. Selected regions are shown in Figure 1.
Effect of epitope insertion on recombinant expression and 
antigenic properties of monomers
In order to evaluate the effect of epitope insertion on the
expression, interaction and antigenicity of the recom-
binant VP6 proteins, insertion mutants were constructed
bearing 14 amino-acids of the V5 epitope at different posi-
tions and expressed in the baculovirus system.
Extracts of Sf9 cells infected with the different recom-
binant baculoviruses exhibited an intense band in
Coomassie-stained polyacrylamide gels, at the electro-
phoretic mobility expected for the recombinant proteins
and absent in extracts of mock-infected Sf9 cells (data not
shown). The apparent molecular weights of the VP6 vari-
ants were slightly higher than wild-typeVP6 and reached
similar expression levels.
To confirm the identity of the chimeric proteins, a mono-
clonal antibody to V5 epitope and an anti-VP6 rabbit pol-
yclonal serum were employed in Western blot
experiments. The extracts of Sf9 cells infected with all the
recombinant baculoviruses exhibited a band with the
expected electrophoretic mobility that strongly reacted
with the monoclonal antibody and was absent in the
extracts of Sf9 AcVP6-infected (Figure 2A), suggesting that
the antigenicity of the V5 epitope was manteined in all the
mutants. The same intense bands were observed when the
polyclonal rabbit serum directed to rotavirus was used
(Figure 2B), but it was possible to observe a partial prote-
olysis in mutants VP6301/V5 and VP6311/V5 which was
only partially prevented with the addition of aprotonine
and leupeptinA.
As VP6311/V5 showed a pronounced cleavage, we contin-
ued this work only with VP6171/V5 and VP6301/V5.
Effect of epitope insertion on trimer and multimer 
formation
In order to evaluate the implicances of the insertion of V5
sequence on the ability of VP6 mutants to oligomerize
into trimers, total extracts from Sf9 cells infected with theVirology Journal 2009, 6:192 http://www.virologyj.com/content/6/1/192
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different recombinant baculoviruses were disrupted at
37°C instead of 100°C, resolved by gel electrophoresis
(in no-reducing or native conditions) and monomers and
trimers detected by Western blot using a SA11 polyclonal
rabbit serum or a V5 monoclonal antibody. As control of
trimers, VP6wt and mutant VP6-V5N were used. This
mutant bears the epitope V5 in the amino terminal of VP6
as it has been reported that insertions at N-terminal of
VP6 did not affect the ability to oligomerize into trimers
(Reddy et al 1992). As previously reported [30], wild type
VP6 was only detected as trimers in these conditions (Fig-
ure 2C). In the same way, mutant VP6-V5N was detected
as trimers. However, we could not detect trimers from
insertional mutants VP6171/V5 or VP6301/V5.
The ability of the insertional mutants to form multimeric
structures was first evaluated by their ability to sediment
through 30% sucrose cushions. Lysates of Sf9 infected
cells from the different recombinant baculoviruses
AcVP6/V5 were ultracentrifugated and the pellets were
disrupted and resolved by SDS-PAGE and Western blot.
The results showed that mutants VP6171/V5 and VP6301/
V5 were able to interact in some multimeric form.
Effects of epitope insertion on VLP assembly and 
exposition of the heterologous sequence
In order to determine the ability of the different VP6
mutants to interact with VP2 to form VLPs, supernatans of
co-infections were analyzed by CsCl gradients and elec-
tron microcopy. By electron microscopy observation, only
VP6171/V5 was able to form VLPs. These VP6171/V5 VLPs
were indistinguishable from wild type VLPs, and the
amount of VLPs per field was very similar (Figure 3).
VP6171/V5 VLPs also exhibited mean diameter compara-
ble with those of VLPs VP6 (Table 1).
In order to determine the epitope exposition on VLPs
VP6171/V5 surface, a sandwich ELISA was performed. The
results suggested that V5 was exposed on the surface of
these VLPs (Figure 4A)
Insertion of the epitope V5 into VP6 sequence Figure 1
Insertion of the epitope V5 into VP6 sequence. A solid ribbon drawing the VP6 trimer is shown at the top. Arrows and 
brackets show only in one chain the amino acids regions of VP6 protein selected in order to insert a heterologous epitope. In 
the lower panel, partial amino acid sequences of VP6 and a series of VP6 mutants were created by replacing the amino acids 
residues indicated by grey boxes with the V5 epitope flanked by SR residues.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VP6 trimer 
 
                    Loop A’A’’              Loop HI 
          168       175         298           315 
VP6wt     RSQPAHDN    PNMTPAVAVLFPNAQPFE 
VP6171/V5    RSQPAHDN    PNMTPAVAVLFPNAQPFE 
VP6301/V5    RSQPAHDN    PNMTPAVAVLFPNAQPFE 
VP6311/V5    RSQPAHDN    PNMTPAVAVLFPNAQPFE 
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To further confirm these results, purified VP6171/V5 VLPs
were immunolabeled with MAb anti-V5 and revealed with
an anti-mouse IgG conjugated to gold particles. Figure 4B
shows that VP6171/V5 VLPs were specificly labeled on
their surface.
Immunogenic features of the VLPs VP6171/V5 mutant
As high quantities of VP6171/V5 were routinely obtained
rendering VLPs with V5 epitope exposed to the surface, we
decided to continue the experiments of immunization
only with this mutant. The immunogenicity of VP6171/V5
VLPs was compared with the same chimeric protein as a
monomer by innoculating groups of five mice with each
preparation. VLPs of wild type VP6 were used to immu-
nize control mice. Antibody titers elicited to anti V5
epitope following two immunizations are given in Table
2. High levels of anti-V5 (~3 log10) antibodies were meas-
ured after 20 days after booster when as little as 300 ng of
chimeric VLPs were administered, representing 9 ng of V5
peptide. In contrast, it was necessary to innoculate 5 μg of
chimaeric monomers to elicit detectable antibody titers to
V5, suggesting that the multimeric presentation of V5 on
the surface of the VLP strongly enhanced their immuno-
genicity.
Discussion
We demonstrated the influence of the insertion of a 14
amino acids heterologous sequence in the ability of VP6
Expression of chimeric VP6/V5 protein Figure 2
Expression of chimeric VP6/V5 protein. Sf9 cells infected with baculovirus AcVP6, AcVP6171/V5, AcVP6301/V5 or 
AcVP6311/V5, were analyzed by western blot using a polyclonal sera anti-VP6 (A) or a MAb anti-V5 epitope (B). In order to 
determine the trimerization ability of the chimeric VP6/V5, cells extracts were analyzed by electrophoresis under native condi-
tions and western blot (C).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
311  301   171   wt    M 
VP6/V5      VP6 
311  301   171   wt    M 
VP6/V5      VP6 
42 
72
KDa  KDa 
72 
42 
A B 
M   wt   V5N  171   301  311 
VP6           VP6/V5 
KDa 
72 
C 
Table 1: Mean diameter of VLPs
VLPs (6 + 2) MEAN DIAMETER
VP6wt 63 ± 2,6 nm
VP6171/V5 69 ± 3,4 nm
These values were obtained through analysis of 100 particles by 
electron microscopy.Virology Journal 2009, 6:192 http://www.virologyj.com/content/6/1/192
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from a simian rotavirus strain to trimerize, multimerize
and interact with VP2 to render chimaeric VLPs. In partic-
ular, when the V5 sequence was inserted at position 171
of VP6, VLPs were indistinguishable of recombinant 2/6
particles, with the inserted epitope protruding from the
particle surface. In addition, these chimeric VLPs elicited
higher antibody titers to the inserted epitope than the
monomeric chimeric protein, suggesting that these chi-
merical VLPs may be a useful vaccine approach for the
multimeric presentation of immunogenic epitopes.
The morphogenesis of rotavirus in mammalian cells has
been widely studied (López et al., 2005), although some
aspects remain less understood. Rotavirus VP6 protein
plays a central rol in virus morphogenesis by establishing
interactions with other structural proteins as well as to the
nonstructural protein NSP4. Core particles assembled
from VP1, VP2 and VP3 acquire an icosahedral layer of
VP6 arranged in trimeric units. Double-shelled particles
are then translocated to the lumen of the endoplasmic
reticulum via NSP4 and virus assembly is completed by
the incorporation of VP4 and VP7. The obtention of rota-
virus-like particles by infection or co-infections of insect
cells by recombinant baculovirus has provided strong evi-
dences on the site of assembly of the major rotavirus struc-
tural proteins VP2 and VP6 and in the characterization of
functional domains. VP2 forms pseudocores of 50 nm of
diameter composed by 60 dimers in the cytoplasm of
infected insect cells observed as aggregates [31], while VP6
alone forms tubular structures composed by a variable
number of trimers [24]. However, when both recom-
binant proteins are simultaneously expressed, VP6 drasti-
cally changes its localization [31] and self-assembly,
rendering double-layered VLPs that are assembled inside
the insect cell and can be recovered from the supernatants
of co-infected cultures.
By the in vitro transcription and translation analysis of
truncated forms of VP6, a large domain involved in
trimerization have been previously characterized span-
ning amino-acidic positions 105 to 328 [32]. By using
VP6 deletion mutants produced in mammalian cells by
recombinant vaccinia virus, the trimerization domain
could be delimited to a region between amino-acids 246
and 314 [30], and the N terminal end of this domain was
postulated between amino-acids 147 and 246. Subse-
quently, by using X-ray crystallography approaches [33] it
was postulated that the amino acids 171 and 172 of VP6
are involved in intra-trimer contacts. In this work, we
observed that the insertion of the V5 sequence in mutant
VP6171 affects trimer formation. This result supports the
hypothesis about the extension of the N-terminal end of
the trimerization domain, extending it at least to the
amino-acid 171.
The analysis of the three-dimensional structure of VP6
from rotavirus group A using X-ray crystallography [33]
determined that the region proposed as a trimerization
domain is localized within a bigger domain formed for β-
strands, denominated domain H (residues 151 to 334).
This amino-acidic organization is characterized by its
rigidity, and any insertion affecting the β-strand structure
may also affect trimer formation. However, bioinformatic
analysis of VP6/V5 chimeras (Swiss prot and Modeller,
results not show) has predicted that the V5 insertions at
positions 171-172, 311-312 and a replacement at posi-
tions 301-308 do not drastically affect the structure of
domain H of the VP6 monomer. However, it was possible
to obtain recombinant VLPs VP6-V5 only when the heter-
olgous epitope was inserted into 171-172 residues. Possi-
bly, the insertion of an heterologous sequence in this
particular amino acidic region of VP6, unstabilizes or pre-
vents the formation of trimers, but the presence of VP2
protein counteracts this negative effect and helps in the
formation of stable VLPs. This fact agrees with the results
obtained by X-ray crystallography where the correct geom-
etry of the viral particle is determined by VP2 [24,33,34].
Rotavirus-derived VLPs were first assessed as an immuno-
logical carrier by Redmond and collegues in 1991. They
demonstrated that peptides coupled to VP6 spheres elic-
ited a greater humoral response than other traditional car-
riers or peptides alone, and that this carrier was not
supressed by the pre-existence of anti-rotavirus antibodies
[27,28]. We demonstrated the influence of the insertion
of an heterologous sequence in the ability of simian rota-
virus VP6 to trimerize, multimerize and interact with VP2
Negative staining of wt or recombinant VLPs Figure 3
Negative staining of wt or recombinant VLPs. In order 
to characterize the VLPs formation, supernants of Sf9 cells 
co-infected with recombinant baculoviruses expressing VP2, 
VP6wt or VP6171/V5 or VP6301/V5 were processed as 
described in Materials and Methods. Particles were adsorbed 
onto carbon-coated grids, staining with 2% uranyl acetate and 
examined immediately. Bar indicates 100 nm.
VP6171/V5  VP6wtVirology Journal 2009, 6:192 http://www.virologyj.com/content/6/1/192
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to render chimeric VLPs. In particular, when the V5
sequence was inserted at position 171-172 of VP6, VLPs
were indistinguishable of recombinant 2/6 particles, with
the inserted epitope exposed on the particle surface. In
addition, these chimeric VLPs elicited higher antibody tit-
ers to the inserted epitope than the monomeric chimaeric
protein, suggesting that this chimeric VLP may be useful
vaccine vehicles for the multimeric presentation of immu-
nogenic epitopes.
Methods
Primer design for insertional mutagenesis
A collection of mutants harboring an XbaI site at the
desired VP6 (SA11 strain) positions were created by PCR
using adequate primers and named according to the posi-
tion of the insertion in the amino-acid sequence. The
internal positions in the amino-acid sequence of VP6
SA11 strain were selected on the basis of the analyses of
spatial conformation of VP6 RF strain deposited on Pro-
tein Data Bank (PDB code: 1qhd) and visualized using the
WebLab Viewer software (Accelrys Software Inc.). Three
regions located in loops exposed onto rotavirus capsid
surface were selected. These amino acidic regions were
171-172, 311-312 and 301 to 308. The primers used for
mutagenesis were: L171-for: TTTCTAGATTGTGATCTATT-
TAGTGT, L171-rev: GGTCTAGACATGATAATTTGAT-
GGGC, L311-for: ATCTAGACCATTCGAACATCAT, L311-
rev: ATCTAGAATTCGGGAATAGTAC, R308-for: CCTCTA-
GACCGAATGCACAGCCATTC and R301-rev: TTTCTAGA-
CATGTTTGGTGGTCTCAG. The XbaI restriction sites are
in bold.
Characterization of recombinant VLPs VP6171/V5 Figure 4
Characterization of recombinant VLPs VP6171/V5. A) Sandwich ELISA to detect epitope exposition onto recombinant 
VLPs surface. Purified wt and recombinant VLPs were captured by polyclonal sera against SA11 strain, then were detected by a 
monoclonal antibody anti-V5 peptide or a polyclonal mouse sera against VP6 protein. B) Microscopy electronic and immuno-
gold labeled. Purified recombinant VLPs VP6171/V5 were loaded onto nickel grids were incubated with a MAb anti-V5 and then 
labeled with a rabbit anti-mouse conjugated with gold.
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Table 2: Anti-V5 epitope antibody titers elicited in mice 
immunized with VLPs VP6171/V5 or monomeric VP6171/V5, 
measured by ELISA
Immunogen Mean log10 ELISA endpoint titer
VLPs 3.08 ± 0.28 (2.6-3.2) †
Monomers 1.88 ± 0.40 (1.7-2.6)
Titers were expressed as log10 of the reciprocal of the highest serum 
dilution, which give OD readings al least twofold higher than those of 
control animals. † Ranges of mean titers are shown in brackets.Virology Journal 2009, 6:192 http://www.virologyj.com/content/6/1/192
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Construction of recombinant baculoviruses
The complete methodology for the construction of recom-
binant baculoviruses has been previously published as a
manual [35]. The VP6 and VP2 sequences used in this
work derived from the simian strain SA11. For VP2 expres-
sion, VP2 coding sequence was first subcloned into
pVL1393 (Pharmingen). For VP6 mutants, PCR amplifica-
tion products were obtained using pBSVP6 (bearing the
entire coding sequence of VP6, kindly provided by Dr. J.
Blackhall) as a template. N-terminal and C-terminal moi-
eties were sequentially cloned into pVL1393, creating an
XbaI site at the junction and replacing two residues in
VP6. For all mutants, the primer VP6-for (AAAGCTTAA-
CATGGATGTCCTATA, bearing a HindIII restriction site)
was used as the forward primer for the N-terminal moiety
and VP6 rev (TGGTACCTCATTTAATGAGCAT, bearing a
KpnI restriction site) was used as the reverse primer for the
C-terminal moiety. Once the two moieties of VP6 with
XbaI sites were cloned together, a synthetic dsDNA con-
structed by annealing of oligonucleotides V5-For and V5-
Rev (V5-for: AATCTAGAGGTAAGCCTATCCCTCTCCTC,
V5-rev: AATCTAGACGTAGAATCGAGACCGAGGAGAG-
GGTT, the XbaI restriction sites are in bold) and coding
for an epitope derived from simian paramyxovirus 5 [29]
was introduced in frame. An extra recombinant VP6
(called VP6-V5N) was constructed bearing the V5 epitope
at the N-terminal end (The primers used were: VP6N-for:
AACCCGGGGATGTCCTATACTCTTTG, VP6N-rev:
AATCTAGATCATTTAATGAGCATGC, V5N-for:
TCCCGGGAGTATGGCTAAGCCTATCCCTAACCCTCTC-
CTC, V5N-rev: TCCCGGGCGTAGAATCGAGACCGAG-
GAGAGGGTT. The XmaI restriction site sare in bold, the
ATG codon is pointed in italic). Relevant sequences of the
transfer plasmids were confirmed by sequencing and Sf9
insect cells were co-transfected with 2 μg of each plasmid
and 0.5 μg of linear AcNPV DNA (Pharmingen) using cell-
fectin (Invitrogen). Resulting recombinant baculoviruses
AcVP2, AcVP6, AcVP6171/V5 AcVP6301/V5 and AcVP6311/
V5 were propagated as previously described [30]. All
recombinant baculoviruses were propagated in Spodoptera
frugiperda Sf9 cells (ATCC) grown at 27°C in TNM-FH
medium (SIGMA) supplemented with 10% foetal bovine
serum (FBS) and antibiotic-antimycotic solution
(GIBCO).
Expression analysis of VP6 mutants
Sf9 cells grown in 25 cm2 flasks were infected at a multi-
plicity of infection (moi) of 5 with each recombinant bac-
ulovirus and 5 days post infection (dpi), cells were lysed
by boiling in presence of 500 μl cracking buffer (50 mM
Tris-HCl pH 6.8, 2% SDS, 0.01% bromo-phenol blue, 1%
2-mercaptoethanol, 10% glycerol) and proteins were
resolved by SDS-PAGE. Recombinant proteins were
detected by Coomassie blue staining or Western blot with
a commercial monoclonal antibody (MAb) directed to the
V5 epitope (Invitrogen) or a rabbit polyclonal serum
against rotavirus SA11.
Analysis of the formation of VP6 trimer, multimers and 
VLPs
For testing the ability of VP6 mutants to form trimers, 5
dpi infected cells grown in 25 cm2 flasks were disrupted in
500  μl cracking buffer (without 2-mercaptoethanol or
DTT), incubated at 37°C for 30 min and subjected to SDS
PAGE under no reducing conditions [36]. Furthermore, 5
dpi infected cells were harvested in TNMC buffer, sub-
jected to three freeze-thaw cycles, sonicated and then elec-
trophoresed under native conditions [36]. Trimers were
detected by Western blot with a MAb to V5 epitope or a
rabbit polyclonal serum against rotavirus SA11.
In order to evaluate the ability of VP6 mutants to mul-
timerize alone or interact with VP2 to form VLPs, Sf9 cells
grown in four 175 cm2 flasks were infected or co-infected
at a moi of 5 for each version of AcVP6 and a moi of 8 for
AcVP2 and 5 dpi supernatants were collected, clarified 10
min at 1,600 × g and VLPs were pelleted by ultracentrifu-
gation through a 30% (w/w) sucrose cushion at 70,000 ×
g for 90 min at 10°C. Pellets were resuspended in 300 μl
of TNMC buffer (10 mM Tris-HCl pH 7, 150 mM NaCl, 1
mM MgCl2, 10 mM CaCl2). Ten μl were disrupted with
cracking buffer and analyzed by SDS-PAGE and Western
blot. Recombinant proteins were detected by a rabbit pol-
yclonal serum against rotavirus SA11 or a mix of this
serum and the Mab directed to V5. The remaining mate-
rial was loaded onto a CsCl gradient (density - 1.32 g ml-
1) and centrifuged 134,000 × g for 18 h at 10°C. The frac-
tion corresponding to VLPs was collected, dialyzed against
TMNC buffer and concentrated by ultracentrifugation at
70,000 × g for 90 min at 10°C. Pellets were resuspended
in 50 μl of TNMC buffer and stored at 4°C for ELISA and
electron microscopy observation.
Electron microscopy
VLPs obtained by ultracentrifugation in CsCl gradients
were loaded onto cupper grids of a 200 mesh, stained with
2% uranyl acetate and analyzed by electronic microscopy
(JEOL SVC-model) at 80 kV.
In order to determinate the heterologous peptide exposi-
tion onto recombinant VLPs surface, an immunogold
labelling was performed. All incubations were carried out
on drops of reagent on strips of parafilm in a covered
chamber. Briefly, recombinant VLPs obtained by ultracen-
trifugation in CsCl gradients were loaded onto nickel
grids and a blocking step was carried out for 30 min with
PBS 1% BSA. Once removed the excess buffer, the grids
were incubated with a drop of monoclonal anti-V5
diluted 1/50 in blocking buffer for 1 h a room tempera-
ture. After each step, grids were washed five times withVirology Journal 2009, 6:192 http://www.virologyj.com/content/6/1/192
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ultrapure water. Then, the samples were incubated with a
drop of anti-mouse antibody conjugated to 10 nm gold
particles (SIGMA) diluted 1/50 in blocking buffer. Finally,
grids were stained in 2% uranyl acetate and analyzed by
electron microscopy.
Characterization of recombinant VLPs by ELISA
Microtitration plates (Maxisorp, Nunc, Rochester, NY)
were coated with 50 μl of an optimal dilution (1/2000) of
a rabbit polyclonal serum against rotavirus-SA11 in car-
bonate buffer pH 9.6 (Na2CO3 15 mM, NaHCO3 35 mM,
pH 9,6), by an overnight incubation at 4°C. The next day,
a blocking step was performed for 1 h at 37°C with PBS,
0.05% Tween-20, 5% horse serum (PBS-T-HS) and 5%
non-fat milk. After each step, plates were washed five
times with washing buffer (PBS, 0.05% Tween-20). Next,
a 50 μl volume of a dilution of purified VP6/VP2 or
recombinant VP6171V5/VP2 VLPs (25 ng/well) was pre-
pared, added it to the plate and incubated for 1 h at 37°C.
After this incubation, optimal sera dilutions of MAb
against V5 epitope or mouse polyclonal against rotavirus
SA11 were transferred to the ELISA plate and incubated
for 1 h at 37°C. Finally, 50 μl of a 1:2000 dilution of
horseradish peroxidase conjugated antibody (KPL, Guild-
ford UK GU2 5GN) in PBS-T-HS were applied for 1 h at
37°C. Then, 50 μl of the substrate solution (ABTS 0.5 mg/
ml (Sigma-Aldrich, St. Louis, MO) in 0.1 M citrate buffer,
pH 4.2 containing 0.03% hydrogen peroxide) were
added, and after incubation at room temperature for 20
minutes absorbance readings at 405 nm were determined.
Each sample was tested in duplicates.
Immunization and evaluation of the humoral immune 
response
Female BALB/c mice (6-8 weeks old) were used for vacci-
nation. Animals received two doses of an oil-based vac-
cine consisting of 300 ng of VLPsVP6171V5 or 5 μg of
monomeric VP6171V5, formulated with incomplete Fre-
und adjuvant (IFA) at days 1 and 21 by the intra-perito-
neal (ip) route. A control group was immunized with
VP6wt. Animals were bled at different times post-vaccina-
tion and were maintained all the time with free access to
sterile food and water.
The humoral immune response against V5 epitope was
evaluated by ELISA. Briefly, a recombinant not related
protein CAT-V5, was produced in E. coli (using pRSET
expression vector) and purified by Ni-NTA agarose (QIA-
GEN). Microtitration plates (Maxisorp, Nunc) were
coated with 75 ng/well of purified CAT-V5 in carbonate
buffer pH 9.6, by an overnight incubation at 4°C. The
next day, plates were blocked with PBS-T-HS and 5% non-
fat milk and subsequently incubated for 1 h at 37°C with
mice serum sample (serial dilutions from 1:50 to 1:5000)
and a secondary anti-mouse-IgG horseradish peroxidase
conjugated antibody (KPL). Primary and secondary anti-
bodies were diluted with PBS-T-HS. After each step, plates
were washed five times with washing buffer. Finally, the
reaction was developed by addition of ABTS 0.5 mg/ml
(Sigma-Aldrich, St. Louis, MO) in 0.1 M citrate buffer pH
4.2 containing 0.03% hydrogen peroxide, and absorbance
readings at 405 nm were determined after incubation at
room temperature. Each sample was tested in duplicate.
Titers were expressed as log10 of the reciprocal of the high-
est serum dilution, which give OD readings al least two-
fold higher than those of control animals.
Abbreviations
VLPs: virus-like particles; PBS-T-HS: PBS, 0.05% Tween-
20, 5% horse serum; CAT-V5: Chloranphenicol Acetyl
Transferase protein fused to V5 epitope.; MAb: mono-
clonal antibody; OD: optical density
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AP: constructed all recombinant baculoviruses, character-
ized the different chimeric VP6-V5, developed a sandwich
ELISA to characterize recombinant VLPs, immunized mice
and evaluated the immune response by ELISA (expressed
and purified a not related recombinant protein CAT-V5 in
order to evaluate the antibody title against V5 epitope).
PM: established optimal conditions to obtain VLPs, pre-
pared all samples to electron microscopy (negativ stain
and immunogold labelling). OT: have been involved in
drafting the manuscript and have given final approval of
the version to be published.
Author's information
A.P.: PhD. in Biology, University of Buenos Aires, Argen-
tina. Assistant Research of Argentine Commission for Sci-
entific and Technological Research (CONICET).
P.M.: Doctoral fellow of CONICET.
O.T.: PhD. in Biology, University of Buenos Aires, Argen-
tina. Research of CONICET and Research of National
Institute of Agricultural Technology (INTA).
Acknowledgements
We are grateful to Dr. Mariana Del Vas for a critical reading of the manu-
script and to Julián Diodati for technical assistance with the electron micro-
scopy. This work was supported in part by a grant from National Institute 
of Agricultural Technology (AEGR 2413).
References
1. Carter JJ, Hagensee M, Taflin MC, Lee SK, Koutsky LA, Galloway DA:
HPV-1 capsids expressed in vitro detect human serum anti-
bodies associated with foot warts.  Virology 1993, 195:456-462.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2009, 6:192 http://www.virologyj.com/content/6/1/192
Page 9 of 9
(page number not for citation purposes)
2. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR,
Schiller JT: A virus-like particle enzyme-linked immunosorb-
ent assay detects serum antibodies in a majority of women
infected with human papillomavirus type 16.  J Natl Cancer Inst
1994, 86:494-499.
3. Roberson JA, Crill WD, Chang GJ: Differentiation of West Nile
and St. Louis encephalitis virus infections by use of noninfec-
tious virus-like particles with reduced cross-reactivity.  J Clin
Microbiol 2007, 45:3167-3174.
4. Yoshii K, Ikawa A, Chiba Y, Omori Y, Maeda J, Murata R, Kariwa H,
Takashima I: Establishment of a neutralization test involving
reporter gene-expressing virus-like particles of tick-borne
encephalitis virus.  J Virol Methods 2009, 161:173-176.
5. Fothergill T, McMillan NA: Papillomavirus virus-like particles
activate the PI3-kinase pathway via alpha-6 beta-4 integrin
upon binding.  Virology 2006, 352:319-328.
6. Sivakumar S, Wang Z, Harrison RL, Liu S, Miller WA, Bonning BC:
Baculovirus-expressed virus-like particles of Pea enation
mosaic virus vary in size and encapsidate baculovirus
mRNAs.  Virus Res 2009, 139:54-63.
7. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW: Immu-
nization with viruslike particles induces long-term protec-
tion of rabbits against challenge with cottontail rabbit
papillomavirus.  J Virol 1996, 70:960-965.
8. Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF, Mac-
Mullen S, Esser MT, Paliard X: Priming of human papillomavirus
type 11-specific humoral and cellular immune responses in
college-aged women with a virus-like particle vaccine.  J Virol
2002, 76:7832-7842.
9. Garcea RL, Gissmann L: Virus-like particles as vaccines and ves-
sels for the delivery of small molecules.  Curr Opin Biotechnol
2004, 15:513-517.
10. Hantz S, Alain S, Denis F: [Human papillomavirus prophylactic
vaccines: stakes and perspectives].  Gynecol Obstet Fertil 2006,
34:647-655.
11. Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, Quan FS, Chen
LM, Donis RO, Compans RW: Induction of long-term protective
immune responses by influenza H5N1 virus-like particles.
PLoS ONE 2009, 4:e4667.
12. O'Neal CM, Crawford SE, Estes MK, Conner ME: Rotavirus virus-
like particles administered mucosally induce protective
immunity.  J Virol 1997, 71:8707-8717.
13. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA,
Newsome JA, Jenson AB, Schlegel R: Systemic immunization
with papillomavirus L1 protein completely prevents the
development of viral mucosal papillomas.  Proc Natl Acad Sci
USA 1995, 92:11553-11557.
14. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari
S: Ebola virus-like particle-based vaccine protects nonhuman
primates against lethal Ebola virus challenge.  J Infect Dis 2007,
196(Suppl 2):S430-437.
15. Grgacic EV, Anderson DA: Virus-like particles: passport to
immune recognition.  Methods 2006, 40:60-65.
16. Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL,
McKenzie IF, Plebanski M: Size-dependent immunogenicity:
therapeutic and protective properties of nano-vaccines
against tumors.  J Immunol 2004, 173:3148-3154.
17. Fields B, Knipe D, Howley P: Field's Virology 3rd edition. Lippincott-
Raven, Philadelphia; 1996. 
18. Kapikian AZ: Viral gastroenteritis.  Jama 1993, 269:627-630.
19. Kapikian AZ, Flores J, Hoshino Y, Glass RI, Midthun K, Gorziglia M,
Chanock RM: Rotavirus: the major etiologic agent of severe
infantile diarrhea may be controllable by a "Jennerian"
approach to vaccination.  J Infect Dis 1986, 153:815-822.
20. Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou YJ, Estes MK:
Characterization of virus-like particles produced by the
expression of rotavirus capsid proteins in insect cells.  J Virol
1994, 68:5945-5952.
21. Gonzalez SA, Affranchino JL: Assembly of double-layered virus-
like particles in mammalian cells by coexpression of human
rotavirus VP2 and VP6.  J Gen Virol 1995, 76(Pt 9):2357-2360.
22. Labbe M, Charpilienne A, Crawford SE, Estes MK, Cohen J: Expres-
sion of rotavirus VP2 produces empty corelike particles.  J
Virol 1991, 65:2946-2952.
23. Zeng CQ, Labbe M, Cohen J, Prasad BV, Chen D, Ramig RF, Estes MK:
Characterization of rotavirus VP2 particles.  Virology 1994,
201:55-65.
24. Lepault J, Petitpas I, Erk I, Navaza J, Bigot D, Dona M, Vachette P,
Cohen J, Rey FA: Structural polymorphism of the major capsid
protein of rotavirus.  Embo J 2001, 20:1498-1507.
25. Banos DM, Lopez S, Arias CF, Esquivel FR: Identification of a T-
helper cell epitope on the rotavirus VP6 protein.  J Virol 1997,
71:419-426.
26. Esquivel FR, Lopez S, Guitierrez XL, Arias C: The internal rotavi-
rus protein VP6 primes for an enhanced neutralizing anti-
body response.  Arch Virol 2000, 145:813-825.
27. Frenchick PJ, Sabara MI, Ready KF, Babiuk LA: Biochemical and
immunological characterization of a novel peptide carrier
system using rotavirus VP6 particles.  Vaccine 1992, 10:783-791.
28. Redmond MJ, Ohmann HB, Hughes HP, Sabara M, Frenchick PJ, Poku
SK, Ijaz MK, Parker MD, Laarveld B, Babiuk LA: Rotavirus particles
function as immunological carriers for the delivery of pep-
tides from infectious agents and endogenous proteins.  Mol
Immunol 1991, 28:269-278.
29. Southern JA, Young DF, Heaney F, Baumgartner WK, Randall RE:
Identification of an epitope on the P and V proteins of simian
virus 5 that distinguishes between two isolates with different
biological characteristics.  J Gen Virol 1991, 72(Pt 7):1551-1557.
30. Affranchino JL, Gonzalez SA: Deletion mapping of functional
domains in the rotavirus capsid protein VP6.  J Gen Virol 1997,
78(Pt 8):1949-1955.
31. Mena JA, Ramirez OT, Palomares LA: Quantification of rotavirus-
like particles by gel permeation chromatography.  J Chroma-
togr B Analyt Technol Biomed Life Sci 2005, 824:267-276.
32. Clapp LL, Patton JT: Rotavirus morphogenesis: domains in the
major inner capsid protein essential for binding to single-
shelled particles and for trimerization.  Virology 1991,
180:697-708.
33. Mathieu M, Petitpas I, Navaza J, Lepault J, Kohli E, Pothier P, Prasad
BV, Cohen J, Rey FA: Atomic structure of the major capsid pro-
tein of rotavirus: implications for the architecture of the vir-
ion.  Embo J 2001, 20:1485-1497.
34. Prasad BV, Wang GJ, Clerx JP, Chiu W: Three-dimensional struc-
ture of rotavirus.  J Mol Biol 1988, 199:269-275.
35. O'Reilly DR, Miller LK, Luckow VA: Baculovirus expression vec-
tors. A laboratory manual.  1994.
36. Auseber F, Brent R, Kingston R, Moore D, Seidman J, Struhc K: Cur-
rent protocols in molecular biology John Wiley and Sons, Inc edn; 1994. 